Message from the President

Video Message From the President

(0:04:52)

Hiroshi Nomura
Representative Director,
President and CEO

My name is Hiroshi Nomura, and I have the honor of serving as Representative Director, President and CEO of Sumitomo Pharma Co., Ltd.

In October 2005, Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceutical Co., Ltd. merged under the trade name Sumitomo Dainippon Pharma Co., Ltd. During the 16 and a half years since the merger, we have undergone a major transformation. We have globalized our business, entered new research areas, and taken on numerous challenges such as large-scale acquisitions and partnerships. For us to grow continuously and evolve toward a new business stage, we have changed the name of the company from "Sumitomo Dainippon Pharma" to "Sumitomo Pharma," and renewed our Group's brand using the globally recognized "Sumitomo" brand, on April 1st, 2022.

Sumitomo Pharma operates every day to achieve its corporate mission "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By directing our efforts into the research and development of new drugs, we aim to provide innovative and valuable pharmaceutical solutions to people not only in Japan but also around the world to realize our corporate mission.

We will remain committed to research and development by taking every available opportunity to assimilate cutting-edge technologies through combinations of a wide variety of avenues, including in-house research, technology in-licensing, and joint research with academia and biotech companies, with the aim of continually discovering valuable pharmaceutical products in our focus research areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, as well as in the area of infectious diseases. In addition, we are engaged in business activities with the goal of becoming the number one company in diabetes in Japan. Furthermore, we will explore new businesses in the healthcare sector and offer solutions other than treatment by pharmaceutical products to gain opportunities that contribute to the well-being of people using digital technologies and other methods.

Through these efforts, we will aim to become a "Global Specialized Player" whose presence is felt throughout the world.

We will also engage in a wide range of other initiatives, including active dialog with diverse stakeholders such as patients, their families, healthcare professionals, our shareholders, other investors, employees, business partners, and the local communities in which we work; social contribution activities in and outside Japan; and promotion of diversity and inclusion. At the same time, by strengthening our corporate governance system and thoroughly ensuring compliance in the conduct of our business, we will continuously enhance our corporate value and thereby contribute to the creation of a more sustainable society.

This change of trade name will motivate all Sumitomo Pharma Group executives and employees to work together with a single purpose of doing our best work to earn and maintain the trust of our stakeholders and continue to be a company that delivers better health and well-being.

On behalf of all of us at Sumitomo Pharma, I would like to sincerely thank you for your ongoing support and encouragement.